
Traditional cost-effectiveness analysis (TCEA) overlooks nonlinear patient health preferences, potentially under-valuing health gains for severe diseases and overvaluing health gains for less severe diseases. Generalized and risk-adjusted cost effectiveness (GRACE) can address this limitation by incorporating patient risk preferences and disease severity, but its implication for valuing treatments for neurodegenerative diseases is unclear. A five-state Markov model was developed to estimate the health economic value of a hypothetical treatment which delayed dementia onset by 30 % versus the standard of care (SoC) for 70-year-old patients diagnosed with mild cognitive impairment. GRACE was implemented using relative risk aversion (RRA) estimates from a U.S. general population survey. Treatment value was measured as risk-and severity adjusted net monetary benefit (RASA-NMB). Risk-neutral TCEA results were computed for comparison. Under TCEA, the hypothetical treatment improved health outcomes by 0.49 quality-adjusted life-years (QALYs) (3.72 vs 3.23 QALYs). Using GRACE, Generalized and Risk-Adjusted QALYs (GRA-QALY) were 3.69 times larger under GRACE than TCEA (2.15 ΔGRA-QALY; 4.91 GRA-QALYs vs 2.76 GRA-QALYs), reflecting additional utility from reduced variance in the distribution of future health and a higher value placed on additional survival relative to health improvement. However, willingness to pay for these gains was 76.4 % lower under GRACE due to high mortality before patients progressed to severe health states ($23,622 per GRA-QALY vs $100,000 per QALY). On net, GRACE increased the net monetary benefit by 3 % compared to TCEA (RASA-NMB = $51,430 vs TCEA NMB = $49,914). In summary, despite large increases in patient utility gains, GRACE had a modest impact on treatment value for neurological conditions causing cognitive impairments.
This paper develops a theoretical model to show how changes in the default system of organ donor registration, along with a Priority Rule, affect society's cadaveric organ donation rate. The developed model is on the lines of Kessler and Roth (2012) and seeks to inspect the hypotheses put forward by Li et al (2013), solely based on their laboratory experiment. The model shows that some of these results can change under specific assumptions regarding the population of potential donors. Among the hypotheses examined in this paper, special emphasis has been given to hypothesis 4, which evaluates whether a nation benefits more from the introduction of the priority rule compared to a change in the default system of organ donation to presumed consent, when the baseline system is explicit consent without the priority rule. The findings suggest that the outcome of such an analysis, in an economy like the United States, will critically depend on how one chooses to quantify the monetary value of Quality Adjusted Life Years (QALYs) gained from organ transplantation and the transaction cost of donor registration. The paper highlights that in the year 2016, the US would have benefited relatively more, in terms of donor registrations for deceased kidney donation, from a change in the default system of organ donation to presumed consent rather than an introduction of the priority rule. This result holds as long as the monetary value of a QALY gained from Deceased Kidney Transplantation is less than $2,068,717.04, at 2016-level prices. The robustness of this result has been confirmed through Monte Carlo Uncertainty Analysis, with statistical significance at the 99 % level.
Chronic obstructive pulmonary disease (COPD) is a group of progressive lung diseases, leading to increased healthcare use, expenditures, and risk of mortality. In June 2024, the Institute for Clinical and Economic Review (ICER) released a traditional cost-effectiveness analysis (CEA) of ensifentrine + background maintenance therapy (BMT) for the treatment of moderate-to-severe COPD. This study's objective is to analyze the sensitivity of ICER's traditional CEA methods to various adjustments to their model, including Generalized Cost-Effectiveness Analysis (GCEA) elements such as generalized risk-adjusted cost-effectiveness (GRACE), dynamic pricing, and stacked cohorts. A Markov model simulated the value of ensifentrine + BMT relative to BMT only for treating moderate-to-severe COPD, with patients transitioning across health states defined by levels of lung functionality. We estimated the annual value-based prices (VBPs) and incremental cost-effectiveness ratios of ensifentrine + BMT relative to BMT using traditional CEA and GCEA methods, including multiple scenario analyses. The VBP of ensifentrine + BMT is estimated at $61,008 when all GCEA elements are included. Relative to the traditional CEA static pricing scenario, GRACE increases VBPs by roughly 10 %, while dynamic pricing increases VBPs by 7-11 %. Stacked cohorts with dynamic pricing increases VBPs by 86-170 %. When including GCEA elements and adjustments to better reflect real-world COPD clinical pathways, ensifentrine + BMT is cost-effective below an annual price of $61,000 at a willingness-to-pay of $150,000 per quality-adjusted life-year.
Neurological conditions adversely impact patients and society due to both quality-of-life decrements and high financial burden. Traditional cost effectiveness methods, however, may undervalue neurological treatments by assuming patients are risk neutral. This study seeks first to quantify insurance value for hypothetical treatments that delay the (i) cognitive and (ii) physical impairments of neurological conditions. Moreover, this study also measures risk preferences over neurological health states to inform parameterization of generalized risk-adjusted cost effectiveness (GRACE) analyses. Two national surveys – one evaluating cognitive impairments and the other mobility impairments – were administered to U.S. residents aged ≥21 years between July 2023 to November 2023. First, a multiple random staircase design was used to elicit respondents’ willingness-to-pay (WTP) for coverage of a hypothetical, new treatment that delayed the progression of cognitive or mobility impairments relative to the standard of care. Insurance value was calculated as the share of the stated preference estimated WTP that exceeded the expected quality-adjusted life year (QALY)-based value assuming risk neutrality. Second, to measure risk aversion, respondents were asked to (i) estimate health-related quality of life (HRQoL) for cognitive and mobility impairment health states using a visual analog scale, and (ii) choose between two hypothetical treatments with probabilistically varying across outcomes following the Holt and Laury (Holt, C. A., and S. K. Laury. 2002. “Risk Aversion and Incentive Effects.” American Economic Review 92 (5): 1644–55). Respondents’ indifference points were inferred from survey responses and used to estimate relative risk aversion (RRA) assuming a constant relative risk aversion utility function. Among n = 295 respondents meeting inclusion criteria for the cognitive survey, 64.9 % were female and the average age was 51 years (SD = 16). WTP for generous insurance coverage of a new treatment delaying cognitive impairment was $646.88 per year compared to $260.80 calculated under traditional (i.e. risk neutral) cost-effectiveness approaches, implying a risk-adjusted cost effectiveness threshold of $248,037 per QALY. Respondents were risk averse over cognitive impairment outcomes, with mean RRA of 1.49 (95 % CI: [1.29, 1.68]). Among the 259 respondents meeting the inclusion requirement for the mobility survey 51.0 % were female and the average age was 49 years (SD = 16 years). WTP for insurance coverage of a new treatment that would prevent progression of mobility impairments was $671.35 per year compared to $133.23 calculated under traditional cost-effectiveness, implying a risk-adjusted cost effectiveness threshold of $502,193 per QALY. Respondents were risk averse over mobility outcomes with mean RRA of 0.68 (95 % CI: [0.51, 0.86]). Due to insurance value, respondents exhibited high willingness to pay for treatments that reduced cognitive and mobility impairments caused by neurological conditions. Individuals were risk averse over both cognitive- and mobility-related neurology health states.
Individuals of Middle Eastern and North African (MENA) ancestry in the US have been the targets of anti-immigrant policies, counterterrorism operations, and vitriolic political rhetoric. Yet, lack of data identifying MENA individuals has prevented systematic evaluation of the impact of these policies and rhetoric on MENA communities' wellbeing, including investment in health capital. We begin to address this gap in knowledge by focusing on the travel ban from majority Muslim countries implemented at the start of the first Trump administration. Using a large, longitudinal medical records database we evaluate the impact of this policy on preventive care use among MENA children in the US, finding decreased well-visits, and associated vaccinations among MENA children. Documenting MENA health outcomes following changes in official US policy is paramount for understanding the full consequences of policies that target underrepresented groups.